DeepMed Research

The Vanderbilt University

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Establishing Lymphedema and Fibrosis Measures in Oral Cancer Patients

Not Applicable

Completed

Conditions: Oral Cavity Cancer
Oropharyngeal Cancer
Lymphedema
Fibrosis

Interventions: Other: LEF measures
Procedure: Technical measure

First Posted Date: 2015-04-09

Last Posted Date: 2021-03-03

Lead Sponsor: Vanderbilt-Ingram Cancer Center

Target Recruit Count: 118

Registration Number: NCT02412241

Locations: 🇺🇸
Vanderbilt-Ingram Cancer Center, Nashville, Tennessee, United States

18F-FES PET/CT in Imaging Patients With Desmoid Tumors

Early Phase 1

Terminated

Conditions: Deep Fibromatosis/Desmoid Tumor
Familial Adenomatous Polyposis

Interventions: Drug: F-18 16 Alpha-Fluoroestradiol
Procedure: Positron Emission Tomography
Procedure: Computed Tomography
Other: Laboratory Biomarker Analysis

First Posted Date: 2015-03-02

Last Posted Date: 2019-10-03

Lead Sponsor: Vanderbilt-Ingram Cancer Center

Target Recruit Count: 3

Registration Number: NCT02374931

Locations: 🇺🇸
Vanderbilt-Ingram Cancer Center, Nashville, Tennessee, United States

Pembrolizumab in Treating Patients With Advanced Uveal Melanoma

Phase 2

Terminated

Conditions: Stage IIIC Uveal Melanoma
Stage IIIB Uveal Melanoma
Stage IIIA Uveal Melanoma
Stage IV Uveal Melanoma

Interventions: Biological: Pembrolizumab
Other: Laboratory Biomarker Analysis

First Posted Date: 2015-02-10

Last Posted Date: 2019-09-18

Lead Sponsor: Vanderbilt-Ingram Cancer Center

Target Recruit Count: 5

Registration Number: NCT02359851

Locations: 🇺🇸
Vanderbilt-Ingram Cancer Center, Nashville, Tennessee, United States
🇺🇸
University of Chicago, Chicago, Illinois, United States

Pain Management Smartphone Application for Patients With Stage III-IV Head and Neck Cancer Undergoing Radiation Therapy

Not Applicable

Completed

Conditions: Pain
Esophageal Cancer
Head and Neck Cancer
Lung Cancer

Interventions: Behavioral: Telephone-Based Intervention
Other: Questionnaire Administration

First Posted Date: 2014-12-24

Last Posted Date: 2016-07-13

Lead Sponsor: Vanderbilt-Ingram Cancer Center

Target Recruit Count: 24

Registration Number: NCT02324881

Locations: 🇺🇸
Vanderbilt-Ingram Cancer Center, Nashville, Tennessee, United States

Trametinib in Treating Patients With Advanced Melanoma With BRAF Non-V600 Mutations

Phase 2

Completed

Conditions: Recurrent Melanoma
Stage IIIB Melanoma
Stage IIIC Melanoma
Stage IV Melanoma

Interventions: Drug: trametinib
Other: laboratory biomarker analysis
Other: pharmacological study

First Posted Date: 2014-11-20

Last Posted Date: 2021-05-28

Lead Sponsor: Vanderbilt-Ingram Cancer Center

Target Recruit Count: 9

Registration Number: NCT02296112

Locations: 🇺🇸
Vanderbilt-Ingram Cancer Center, Nashville, Tennessee, United States
🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States

and more 1 locations

Quantitative MRI in Assessing Disease in Patients With Brain Tumors

Not Applicable

Terminated

Conditions: Tumors Metastatic to Brain
Unspecified Adult Solid Tumor, Protocol Specific

Interventions: Procedure: diffusion-weighted magnetic resonance imaging
Procedure: chemical exchange saturation transfer magnetic resonance imaging
Procedure: dynamic contrast-enhanced magnetic resonance imaging
Procedure: dynamic susceptibility contrast-enhanced magnetic resonance imaging

First Posted Date: 2014-10-20

Last Posted Date: 2018-05-29

Lead Sponsor: Vanderbilt-Ingram Cancer Center

Target Recruit Count: 10

Registration Number: NCT02269111

Locations: 🇺🇸
Vanderbilt-Ingram Cancer Center, Nashville, Tennessee, United States

Predicting Development of Diabetes Mellitus in Patients Undergoing Allogeneic Stem Cell Transplant

Not Applicable

Terminated

Conditions: Diabetes Mellitus
Malignant Neoplasm

Interventions: Procedure: assessment of therapy complications
Other: laboratory biomarker analysis

First Posted Date: 2014-09-15

Last Posted Date: 2019-07-18

Lead Sponsor: Vanderbilt-Ingram Cancer Center

Target Recruit Count: 22

Registration Number: NCT02240381

Locations: 🇺🇸
Vanderbilt-Ingram Cancer Center, Nashville, Tennessee, United States

FDG-PET in Advanced Melanoma

Not Applicable

Terminated

Conditions: Stage IV Melanoma
Stage IIIA Melanoma
Stage IIIB Melanoma
Stage IIIC Melanoma
Recurrent Melanoma

Interventions: Diagnostic Test: [18F]fluorodeoxyglucose
Other: Molecular assays on biopsied tissue
Device: positron emission tomography
Device: computed tomography

First Posted Date: 2014-09-10

Last Posted Date: 2017-04-13

Lead Sponsor: Vanderbilt-Ingram Cancer Center

Target Recruit Count: 3

Registration Number: NCT02236546

Locations: 🇺🇸
Vanderbilt-Ingram Cancer Center, Nashville, Tennessee, United States

Home-Based Lymphedema Care Program (HBLCP) in Improving Lymphedema Self-Care in Head and Neck Cancer Survivors

Not Applicable

Terminated

Conditions: Head and Neck Cancer
Lymphedema

Interventions: Behavioral: Home-based Lymphedema Care Program

First Posted Date: 2014-06-23

Last Posted Date: 2018-01-25

Lead Sponsor: Vanderbilt-Ingram Cancer Center

Target Recruit Count: 20

Registration Number: NCT02170272

Locations: 🇺🇸
Vanderbilt-Ingram Cancer Center, Nashville, Tennessee, United States

Prospective Outcomes of Second-Line Therapy in Acute Graft-Versus-Host Study Including ECP (POSTAGE)

Terminated

Conditions: Graft Versus Host Disease

Interventions: Other: medical chart review
Other: quality-of-life assessment

First Posted Date: 2014-05-30

Last Posted Date: 2019-10-17

Lead Sponsor: Vanderbilt-Ingram Cancer Center

Target Recruit Count: 19

Registration Number: NCT02151539

Locations: 🇺🇸
Mayo Clinic in Arizona, Scottsdale, Arizona, United States
🇩🇪
Klinikum der Universität Regensburg, Regensburg, Germany
🇬🇧
Nottingham City Hospital, Nottingham, United Kingdom

and more 4 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy